Guzmán-Uribe P, Rosas-López A, Zepeda-León J, Crespo-Solís E

Language: English
References: 47
Page: 130-140
PDF size: 178.87 Kb.

ABSTRACT

Background. Acute leukemias are hematopoietic malignancies that may be accompanied by hemostatic abnormalities. In general, information on the frequency of thrombotic events, their clinical characteristics and survival in adult patients with acute leukemia is still scarce and controversial. Objectives. To describe the frequency of thrombotic events, their clinical characteristics and survival of adult patients with acute leukemia at the Instituto Nacional de Ciencias Médicas y Nutrición, Salvador Zubirán, Mexico City. Material and methods. A patient cohort, diagnosed and treated between October 2003 and December 2009, was retrospectively analyzed in terms of thrombotic events, frequencies and survival curves. Results. We analyzed 181 patients with a median age of 33 years, 80 were female (44.2%). Fifteen cases with thrombosis (8.3%) were documented and in 53.3% of cases, they were related to the use of a central venous catheter. The median time to development of thrombosis was 92 days; 33.3% of events occurred during the first 30 days after diagnosis. The incidence of thrombosis in patients receiving L-asparaginase was 15%. Of the 15 patients with thrombosis, 27% were alive and without evidence of disease at last follow-up, and 73% had died; disease progression was the most common cause of death (81.8%). None of the thrombotic events had an impact on mortality. Median overall survival (OS) was 349 days. Conclusions. The incidence of thrombosis in this adult acute leukemia population is comparable to that reported in the literature. Only a third of cases occurred during the first month after diagnosis; however, 93.3% of patients developed a thrombotic event during the first year after the diagnosis of acute leukemia. All cases were symptomatic and central venous catheter-related thrombosis was the most frequent presentation in this group. Survival curves comparing patients with and without thrombosis were similar. Prospective studies are necessary in order to assess the risk factors fostering thrombosis in adult patients with acute leukemia.

REFERENCES

1. Bick RL, Strauss FJ, Frenkel PE. Thrombosis and hemorrhage in oncology patients. Hematol Oncol Clin North Am 1996; 10: 875-907.

2. Connolly G, Khorana A. Emerging Risks stratification approaches to cancer-associated thrombosis: risk factors, biomarkers and a risk score. Thromb Res 2010; 125 (Suppl. 2): S1-S7.

3. Khorana A. Venous Thromboembolism and prognosis in cancer. Thromb Res 2010; 125: 490-3.

4. Hillen HF. Thrombosis in Cancer Patients. Ann Oncol 2000; 11 (Suppl. 3): 273-6.

5. Lee AY, Levine MN. Venous thromboembolism and cancer: Risks and outcomes. Circulation 2003; 107: I17-I21.

6. Falanga A, Marchetti M. Venus Thromboembolism in the Hematologic Malignancies. J Clin Oncol 2009; 27: 4848-57.

7. Khorana AA, Francis CW, Culakova E, Kuderer NM, et al. Thromboembolism is a leading cause of death in cancer patients receiving outpatient chemotherapy. J Thromb Haemostasis 2007; 5: 632-4.

8. Kolitz JE, Rakel RE, Bope ET. Acute leukemias in adults. In: Conn’s Current Therapy. Saunders 2008; 6: 441-6.

9. Falanga A, Rickles FR. Management of thrombohemorrhagic syndromes (THS) in hematologic malignancies. Hematology Am Soc Hematol Educ Program 2007; 165-71.

10. Ziegler S, Sperr WR, Knöbl P, Lehr S, et al. Symptomatic venous thromboembolism in acute leukemia: incidence, risk factors, and impact on prognosis. Thromb Res 2005; 115: 59-64.

11. Mohren M, Markmann I, Jentsch-Ullrich K, Koenigsmann M, et al. Increased Risk of venous thromboembolism in patients with acute leukemia. Br J Cancer 2006; 94: 200-02.

12. Ku G, White R, Chew H, Harvey DJ, et al. Venous thromboembolism in patients with acute leukemia: incidence, risk factors, and effect on survival. Blood 2009; 113: 3911-7.

13. De Stefano V, Sora F, Rossi E, Chiusolo P, et al. The risk of thrombosis in patients with acute leukemia: Occurrence of thrombosis at diagnosis and during treatment. J Thromb Haemost 2005; 3: 1985-92.

14. Melillo L, Grandon E, Colaizzo D, Cappucci F, et al. Symptomatic venous thromboembolism and thrombophilic status in acute adult leukemia: A single-center experience of 114 patients at diagnosis. Acta Haematol 2007; 117: 215-20.

15. Wun T, White RH. Venous Thromboembolism in patients with acute leukemia, lymphoma and multiple myeloma. Thromb Res 2010; 125 (Suppl. 2): S96-S102.

16. Crespo-Solis E. Thrombosis in acute leukemia. Hematology 2012; (Suppl. 1); 17: S169-S173.

17. Menell JS, Cesarman GM, Jacovina AT, McLaughlin MA, et al. Annexin II and bleeding in acute promyelocitic leukemia. N Engl J Med 1999; 340: 994-1004.

18. Kasthuri RS, Taubman MB, Mackman N. Role of Tissue Factor in Cancer. J Clin Oncol 2009; 27: 4834-8.

19. Vargas-Ruiz A. Cáncer y Trombosis. Rev Hemo Trombo 2010; 3: 1-12.

20. Matzdorff AC, Green D. Overview of Cancer and Thrombosis. In: Rosen ST, Green D, Kwaan HC. Coagulation in cancer. 1st. Ed USA: Springer; 2009, p. 83-94.

21. Harlev D, Zaidman I, Sarig G, Ben Arush MW, et al. Prophylactic therapy with enoxaparin in children with acute lymphoblastic leukemia and inherited thrombophilia during L-asparaginase treatment. Thromb Res 2010; 126: 93-7.

22. Nowak-Göttl U, Heinecke A, Von Kries R, Nürnberger W, et al. Thrombotic events revisited in children with acute lymphoblastic leukemia. Impact of concomitant Escherichia coli asparaginase/ prednisone administration. Thromb Res 2001; 103: 165-72.

23. Rickles F, Falanga A, Montesinos P, Sanz MA, et al. Bleeding and thrombosis in acute leukemia: What does the future of therapy look like? Thromb Res 2007; 120 (Suppl. 2): S99-S106.

24. Khorana A, Connolly G. Assessing risk of venous thromboembolism in the patient with cancer. J Clin Oncol 2009; 27: 4839-47.

25. Connolly GC, Khorana AA, Kuderer NM, Culakova E, et al. Leukocytosis, thrombosis and early mortality in cancer patients initiating chemotherapy. Thromb Res 2010; 126: 113-8.

26. Ramos Peñafiel CO, Martínez Murillo C, Castellanos Sinco H, Montaño Figueroa E, et al. Frecuencia de trombosis venosa en pacientes con Leucemia Linfoide Aguda durante la terapia de inducción: Protocolo Institucional HGMLAL 07/09. Rev Hemo Trombo 2012; 3: 1-5.

27. Swerdlow SH, Campo E, Harris NL, et al (eds.): WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. IARC: Lyon; 2008.

28. Byrd J, Mrozek K, Dodge R, Carroll AJ, et al. Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse and overall survival in adult patients with the novo acute myeloid leukemia: results from Cancer and Leukemia Group B, CALGB 8461. Blood 2002; 100: 4325-36.

29. Omura G, Vogler R, Lefante J, Silberman H, et al. Treatment of acute myelogenus leukemia: Influence of three induction regimens and manteinance with chemotherapy and manteinance of BCG immunotherapy. Cancer 1982; 49: 1530-6.

30. Buitrón-Santiago N, Arteaga-Ortiz L, Rosas-López A, Aguayo A, et al. Experiencia del INCMNSZ en pacientes adultos con leucemia mieloide aguda. Cohorte 2003-2008. Rev Invest Clin 2010; 62: 100-08.

31. Thomas D, Cortes J, O’Brien S, Pierce S, et al. Hyper-CVAD Program in Burkitt´s-Type Adult Acute Lymphoblastic Leukemia. J Clin Oncol 1999; 17: 2461-70.

32. Arteaga-Ortiz L, Buitrón-Santiago N, Rosas-López A, Rosas- Arzate G, et al. Experiencia del INCMNSZ en pacientes adultos con leucemia linfoide aguda. Cohorte 2003-2007 con esquemas de tratamiento Hiper-CVAD y Protocolo 0195. Rev Invest Clin 2008; 60: 459-69.

33. Sanz MA, Martin G, Gonzalez M, León A, et al. Risk adapted treatment of acute promyelocytic leukemia with all-trans-retinoic acid and anthracycline monochemotherapy: a multicenter study by the PETHEMA group. Blood 2004; 103: 1237-43.

34. Cortelezzi A, Moia M, Falanga A, Pogliani EM, et al; CATHEM Study Group. Incidence of thrombotic complications in patients with haematological malignancies with central venous catheters: a prospective multicentre study. Br J Haematol 2005; 129: 811-17.

35. Rooden CJ, Tesselaar MET, Osanto S, Rosendaal FR, et al. Deep vein thrombosis associated with central venous catheters - a review. J Thromb Haemost 2005; 3: 2409-19.

36. Payne JH, Vora AJ. Thrombosis and acute lymphoblastic leukemia. Br J Haematol 2007; 138: 430-45.

37. Korte W, Fletges A, Baumgartner C, Ullmann S, et al. Increased thrombin generation during fibrinogen and platelet recovery as an explanation for hypercoagulability in children with L-asparaginase therapy for ALL or NHL: a preliminary report. Klin Padiatr 1994; 206: 331-3.

38. Sutor AH, Mall V, Thomas KB. Bleeding and thrombosis in children with acute lymphoblastic leukemia, treated according to the ALL-BFM-90 protocol. Klin Padiatr 1999; 211: 201-04.

39. Hunault-Berger M, Chevallier P, Delain M, Bulabois CE, et al; GOELAMS (Groupe Ouest-Est des Leucémies Aiguës et Maladies du Sang). Changes in antithrombin and fibrinogen levels during induction chemotherapy with L-asparaginase in adult patients with acute lymphoblastic leukemia or lymphoblastic lymphoma: use of supportive coagulation therapy and clinical outcome. The CAPELAL study. Haematologica 2008; 93: 1488-94.

40. Samama MM. An epidemiologic study of risk factors for deep vein thrombosis in medical outpatients: the Sirius study. Arc Int Med 2000; 160: 3415-20.

41. Ay C, Vormittag R, Dunkler D, Simanek R, et al. D-Dimer and prothrombin fragment 1+2 predict venous thromboembolism in patients with cancer: results from the Vienna Cancer and Thrombosis Study. J Clin Oncol 2009; 27: 4124-9.

42. Montesinos P, De la Serna J, Vellenga E, et al. Incidence and risk factors for thrombosis in patients with acute promyelocytic leukemia. Experience of the PETHEMA LPA96 and LPA99 protocols. Blood (ASH Annual Meeting Abstracts) 2006; 108: 1503.

43. Dally N, Hoffman R, Haddad N, Sarig G, et al. Predictive Factors of bleeding and thrombosis during induction therapy in acute promyelocytic leukemia - a single center experience in 34 patients. Thromb Res 2005; 116: 109-14.

44. Breccia M, Avvisati G, Latagliata R, Carmosino I, et al. Occurrence of thrombotic events in acute promyelocytic leukemia correlates with consistent immunophenotypic and molecular features. Leukemia 2007; 21: 79-83.

45. Athale UH, Chan AKC. Thrombosis in children with acute lymphoblastic leukemia. Part I. Epidemiology of thrombosis in children with acute lymphoblastic leukemia. Thromb Res 2003; 11: 125-31.

46. Sorensen HT, Mellemkjaer L, Olsen JH, Baron JA. Prognosis of cancers associated with venous thromboembolism. N Engl J Med 2000; 343: 1846-50.

47. Kuderer NM, Ortel TL, Francis CW. Impact of Venous Thromboembolism and Anticoagulation on Cancer and Cancer Survival. J Clin Oncol 2009; 27: 4902-11.